生命科学资讯

Evinova reels in AI clinical development deals with Astellas and AstraZeneca

FDA freezes enrollment in MacroGenics cancer trial after patient death

Harbour ships CTLA-4 asset to form new biotech in $1.1B biobucks deal

GSK explores frontiers of siRNA with $1B deal for 2 drugs from Chinese biotech

Labcorp, PathAI expand partnership to offer AI tech for digital pathology diagnostics

Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study

Allurion stock balloons as FDA signs off on its weight loss gastric system

Medtronic's diabetes business MiniMed eyes $784M IPO

Organon pays $27.5M upfront to license Sebela's hormone-free copper IUD

Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking

Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months

‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific

Angelini nocks an AI arrow with $120M Quiver Bioscience deal

UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies

FDA issues safety alert on Trividia blood glucose monitors

Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials

Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail

MoonLake's phase 2 arthritis win kicks off pivotal year for IL-17 nanobody

Assessing Myelin Formation and Therapeutic Response Using 3D Organoids

iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004